- Open Access
Computational cell fate modelling for discovery of rewiring in apoptotic network for enhanced cancer drug sensitivity
© Mishra et al.; licensee BioMed Central Ltd. 2015
- Published: 21 January 2015
The ongoing cancer research has shown that malignant tumour cells have highly disrupted signalling transduction pathways. In cancer cells, signalling pathways are altered to satisfy the demands of continuous proliferation and survival. The changes in signalling pathways supporting uncontrolled cell growth, termed as rewiring, can lead to dysregulation of cell fates e.g. apoptosis. Hence comparative analysis of normal and oncogenic signal transduction pathways may provide insights into mechanisms of cancer drug-resistance and facilitate the discovery of novel and effective anti-cancer therapies. Here we propose a hybrid modelling approach based on ordinary differential equation (ODE) and machine learning to map network rewiring in the apoptotic pathways that may be responsible for the increase of drug sensitivity of tumour cells in triple-negative breast cancer. Our method employs Genetic Algorithm to search for the most likely network topologies by iteratively generating simulated protein phosphorylation data using ODEs and the rewired network and then fitting the simulated data with real data of cancer signalling and cell fate. Most of our predictions are consistent with experimental evidence from literature. Combining the strengths of knowledge-driven and data-driven approaches, our hybrid model can help uncover molecular mechanisms of cancer cell fate at systems level.
- Genetic Algorithm
- Epidermal Growth Factor Receptor
- Cell Fate
- Partial Little Square Regression
- Dynamic Time Warping
The objective of anti-cancer therapeutics is to kill cancer cells with minimum damage to the healthy cells. To this end, a solid understanding of the cell fate decisions (e.g. apoptosis, proliferation) of different cells under various conditions would be required. It is well known that signalling pathways play crucial roles in the regulation of cancer cell fate . However, it is challenging to understand the dynamics of signal transduction at systems level, due to non-linearity of the network dynamics, e.g. feedback and crosstalk. In cancer cells, this becomes even more complicated due to various types of alterations (e.g. DNA mutations, genome rearrangement, epigenetic changes, and pathway alterations). These alterations allow cancer cells to adapt to new conditions and evolve drug resistance. Therefore, to find effective anti-cancer therapies, cancer-specific alterations in the signalling pathways must be taken into account. Moreover, it is desirable to understand how cancer cells respond to different combinations of drugs, and how drug sensitivity can be enhanced. Genomic and proteomic data of cellular responses to drugs, synchronized with cell fate observations, would shed light on cancer drug effects at systems level. However, even if sufficient data are available, it is challenging to construct a model of cell signalling to explain the data and make accurate predictions. As more "omics" data about cancer are available recently, computational methods for modelling and discovery of cancer cell fate are becoming more important.
Cancer cell fate in response to drugs has been studied with both discrete and continuous models using knowledge driven approaches. For example, the study in  focused on discrete modelling of the apoptosis network, by constructing a model for cell fate with 25 key regulatory genes (e.g. Casp3, BCL2, XIAP, etc.). Cell survival pathways with cell death (necrosis and apoptosis) pathway were combined to model three cell fates, namely apoptosis, proliferation and survival. GINsim  software was used to perform simulation to assess the importance of Cytokines (e.g. TNF, FASL) in deciding the cell fate. In another study, Hong et al.  analysed the continuous model of apoptosis triggered by the drug Cisplatin. They initially constructed apoptosis pathways using existing literature. This model was configured to respond to the external stimulus, i.e. the drug Cisplatin. To analyse the functions of various signalling pathways and their crosstalk, Hong et al. integrated three apoptosis pathways, namely death receptors (e.g. FasL) induced pathway, mitochondrial pathway and ER stress pathway. Using their differential equation based model they found that the apoptosis caused by Cisplatin was dependent on doses and time. The level of apoptosis was almost stagnant at higher concentration of drug. They also observed that mitochondrial pathway has strongest effect on apoptosis (among the three pathways) .
On the other hand, data driven modelling of signalling pathways is a promising approach to uncover regulatory mechanism for cancer cell fate. The study in  investigated three lines of breast tumour, namely BT-20, MDA-MB-453 and MCF7, for their responses to various combinations of exposure to several genotoxic drugs and signalling inhibitors. The authors found that it was the pre-treatment, rather than co-treatment or post-treatment, of a subset of TNBCs with Epidermal Growth Factor Receptor (EGFR) inhibitors that can enhance the sensitivity of tumour cells in their apoptosis response to DNA-damaging chemotherapy. The study suggested that such a treatment may lead to the rewiring of oncogenic signalling pathways which has the potential to make cancer cells more susceptible to death. It was further reported that the inhibition of EGFR in a time-staggered way may be responsible for sensitising tumour cells to genotoxic drugs. However, simultaneous co-administration of inhibitors and genotoxic drug could not make the tumour cells less tumorigenic. To test these hypotheses, the study systematically investigated a series of drug combinations for their effects on breast cancer cells. The study suggests that rewiring inside the tumour cells is responsible for the increase of drug sensitivity, but it is not clear where and how the rewiring happens. The rewiring involves alterations of signalling pathways such as addition or deletion of edges in the network, change in reactions rates, and change in the concentration of molecules. Since it is more challenging to directly observe rewiring signalling pathways by wet lab experiments, computational methods for predicting rewiring from data would be useful for study of cancer drug effect and cell fate decisions.
In this paper, we propose a hybrid modelling approach that combines the advantages of knowledge-driven and data-driven approaches for modelling cancer signalling pathways and cell fate decisions. From a generic apoptotic network, we simulate the time series data of signalling proteins using ODEs based on a network candidate modified from the generic network by in silico rewiring; then the simulated data are compared with the real data. This in in silico rewiring, simulation and data fitting is repeated iteratively to improve the goodness of fit using Genetic Algorithm. Through such an optimisation we can detect the topology alterations of the network that allows close fitting of model to the real data. As such, network rewiring can be inferred from real data. Most of rewiring events predicted by our model are supported by existing literature.
Our work is broadly organised in three interrelated parts. We initially constructed a basic apoptosis network (say N1) which is free of abnormal mutation and represents signalling pathways inside a healthy cell. We used the biological data for our studies based on the phosphorylation levels of signalling proteins and phenotypic responses taken from the biological experiments conducted in . Hereafter, we call this data set as "Yaffe's data". We compared the simulation data from this network with the Yaffe's data using Genetic Algorithm and Dynamic Time Warping for DMSO treatment and derived a tumorigenic network (say N2). Then we modified N2 to fit with Yaffe's data to derive a drug sensitive network (say N3). N1 was constructed directly from literature; N2 consisted of edges added and deleted from N1 by Genetic Algorithm; N3 consisted of edges added and deleted from N2 by Genetic Algorithm.
The Yaffe's data set contains six types of cellular phenotypic responses from three cancer cell lines, namely triple negative BT-20, Hormone sensitive MCF-7 and HER2 overexpressing MDA-MB-453. The six phenotypes are Apoptosis, Proliferation, G1, S, G2 and M. These phenotypic responses are linked with on 35 signalling proteins (only 32 available in the published data set). The signalling molecule data available contains 8 time points (0, 1, 2, 3, 4, 5, 6 and 7). The phenotypic responses were measured at five time points (0, 6, 7, 8 and 9), over 24 hours in the panel of breast cancer cell lines. The cell fates and signalling data are available for all the three cell lines. The measurements of the signalling and cell fate data have been done for six treatments namely DMSO, TAR, DOX, DT, T-D and D-T. The apoptosis level is reportedly high for the T-D treatment, meaning the cells are now less tumorigenic for this treatment and thereby more susceptible to death induced by DNA damage response pathways. The study in  employs several mathematical modelling approaches to relate signalling data to cell phenotypes. Principal component analysis (PCA) was used to identify co-variation between signals, whereas partial least-squares regression (PLSR) was used to identify co-variation between molecular signals and corresponding cellular phenotypic responses. In both PCA and PLSR modelling, the input vectors contained quantitative measurements of the signalling proteins.
Apoptosis network construction
We constructed a generic apoptosis network consisting of 22 signalling proteins including 18 proteins from the biological experiment conducted in . The authors of  provided Variable Importance in Projection (VIP) scores for different selected proteins to demonstrate how the selected proteins were useful for predicting apoptosis of different cell lines. For example, proteins with VIP score > 1 were important variables, proteins with VIP score < 0.5 were unimportant variables. Since our goal is to test the goodness of fit of our model with Yaffe's data, we selected proteins that have been measured in the experiment. Also, our signalling network includes molecules based on the prior knowledge from several pathways playing critical roles in inducing cell death, which include DNA damage response and cell death pathways, stress response pathways, etc.
Beclin-1 is an autophagy protein that interacts with Bcl-2, an anti-apoptotic protein, and they form a complex, to facilitate a switch from autophagy to apoptosis and vice-versa. The activity of Beclin-1, owing to the complex formation of Bcl-2:Beclin-1 complex, is suppressed by Bcl-2 protein [11, 12]. STAT3 is an important gene due to its roles in regulating cell fate including cell survival and cell growth. Experimental results have shown that a decreased level of STAT3 leads to a reduced level of Bcl-2 . Activation of STAT3 gene stimulates transcription of quite a few cell fate controlling genes, which include some of the members of Bcl-2 protein family . The proteins Wee1 and Cdk1 (Cyclin-dependent kinase 1) play very important roles in regulating cell cycle. During mitosis, the size of a cell is controlled by the inhibition of Cdk1 by Wee1 which prevents the cell from going into mitosis. The suppression of Cdk1 by Wee1 is done by phosphorylation of Cdk1 . Cdk1 in turn phosphorylates Bcl-2 and suppresses its activity . The EGF receptor (EGFR) is a cell membrane protein receptor with high affinity for several specific proteins (ligands) including Epidermal Growth Factor (EGF). EGFR further activates many targets including Jun N-terminal kinases (JNKs). Mutation in EGFR may lead to its uncontrolled expression which can potentially cause uncontrolled cell growth, which is a hall mark of cancer . The Bcl-2-associated death promoter (BAD), another member protein from Bcl-2 group of proteins, is highly pro-apoptotic. JNK can inhibit apoptosis by phosphorylating BAD protein . Trimeric Tumor Necrosis Factor (TNF) activates multiple signalling pathways which in turn lead to apoptosis. TNF interacts with death domain (DD) protein TRADD. TRADD in turn has been shown to have high affinity for RIP . Casp3 mediates cleavage of multiple proteins and causes DNA fragmentation which eventually leads to apoptosis .
Simulation with ODE
Differential equations for the basic apoptosis network N1 (Figure 1)
Rate of Change
- [Casp6]·rc11 + [Casp9]·rc12
+[Wee1]·rc13 - [CDK1]·rc14
- [JNK]·rc15 + [EGFR]·rc17
- [BID]·rc16 - [BID]·rc25
- [EGFR]·rc17 - [EGFR]·rc32;
- [PUMA]·rc19 + [p53]·rc27
- [Casp3]·rc1 + [XIAP]·rc2 + [SMAC]·rc4 + [Casp8]·rc7 - [Casp3]·rc8 +[Casp9]·rc9 +[Casp6]·rc11 + [MOMP]·rc30
- [Casp9]·rc9 - [Casp9]·rc12 + [PUMA]·rc19 - [Casp9]·rc24 + [BCL2]·rc26
- [HER2]·rc20 - [HER2]·rc31
- [Casp8]·rc3 + [RIP1]·rc6 - [Casp8]·rc7 + [Casp3]·rc8 + [BID]·rc25 +[EGFR]·rc
- [XIAP]·rc2 + [SMAC]·rc21 + [Casp9]·rc24 + [HER2]·rc31
+[Casp8]·rc3 - [SMAC]·rc4 + [BCL2]·rc5 - [SMAC]·rc21 + [MOMP]·rc29
- [BCL2]·rc5 + [p53]·rc10 + [CDK1]·rc14 + [JNK]·rc15 +[BID]·rc16 +[STAT3]·rc22 - [BCL2]·rc26
- [RIP1]·rc6 + [TNFR]·rc23
- [p53]·rc10 + [AKT]·rc18 - [p53]·rc27
- [AKT]·rc18 + [HER2]·rc20
+[DAPK1]·rc28 - [MOMP]·rc29 - [MOMP]·rc30
where rc18 is the binding rate constant from AKT to p53 and [AKT] is the concentration of the AKT molecule. Also, rc20 represents the binding rate constant for HER2 to AKT. Similarly, for p53, variables in the corresponding equation incorporate information for the molecular concentrations and the binding rate constants for AKT and p53.
In our study, the ODEs were solved using the standard Matlab library function ode45. This function can interpret the differential equations in the form of rate reactions. The ode45 accepts the initial values of the molecules and the time duration in the form of function parameters [20, 21]. Using this procedure, we derived the rate equations and time course data for all twenty-two signalling proteins. The initial concentrations of the signalling molecules were set to dimensionless numeric value of one . Some of the rate constants were taken directly from the literature. These include Casp9 & Casp3, Casp9 & XIAP, Casp8 & BID, Casp3 & XIAP, Casp3 &Casp8, Casp3 & Apop, p53 & PUMA, Casp3 & Casp6 and XIAP & SMAC [4, 23, 24]. The remaining parameters were generated randomly but we verified them by Partial Least Square Regression (PLSR) test. We also performed sensitivity analysis of the model parameters by varying the model parameters to ensure overall robustness of the model to the small variations of parameters (see result section for PLSR test and sensitivity analysis).
We applied the Genetic Algorithm to search for the network topologies that fit the real data well, in order to uncover the rewiring inside the tumour cells. There are several optimisation techniques available in the literature which can be used to search for the network topologies. These techniques include, for example, Simulated Annealing, Evolution Strategies, Genetic Algorithm, Evolutionary Programming etc. Simulated Annealing has population size of only one which represents current solution, thus the solution space is not as wide as GA. Similarly, Evolutionary Programming can only use mutation operator. By contrast, Genetic Algorithms have several solutions in the beginning and crossovers can be performed to generate the diversity in the population of network structures. While the probabilistic selection of GA helps us simulate the stochastic biochemical networks in better ways, Evolution Strategies uses deterministic selection [25, 26]. After comparing these techniques, we decided to use Genetic Algorithm in our study. As a global search technique, GA is considered to be very robust as it makes very few assumptions about the problem under consideration .
Genetic Algorithm for finding mutation in apoptotic network.
INPUT: Objective function, Network Topology(NT) in the form of Adjacency vector of size n × n, reaction rate constants vector of size n × n, maximum number of generations Max num gen for the algorithm, biological data measurements
OUTPUT: A vector consisting topology of best uncovered network, score vector S, for such uncovered networks
1. NT0 ⇐ topology
2. RC0 ⇐ rate constants
3. Max_num_itr ⇐ total number of iteration allowed
4. S0 ⇐ 0
5. Derive Population P (randomly generated networks)
6. For max_ num_gen times do:
7. Derive rate equations for each network in P
8. Solve each of the Rate equations
9. Derive numerical solutions (time series data)
10. Compare the simulation results with Yaffe's data using DTW Objective function and calculate the Score
11. Select 50 best score
12. Perform crossover among best selected networks to formulate next generation, total of 100 networks again. The crossover points are selected based on random numbers. The networks to be crossed over are selected randomly.
13. Perform mutation for each bit with the probability of 0.01, for each of the hundred networks.
14. Set new population P = mutated network from step 13
15. Check for the convergence.
16. If network not converged, go to step 5
7. Output solution set.
The network topology is represented by an adjacency matrix. For each edge between two nodes in the network there is a Boolean value of ' 1' in the matrix, and a ' 0' entry represents the absence of connection between the corresponding nodes. The adjacency matrix can be modified in Genetic Algorithm as follows . We initially derive the chromosome (vector of 1 × 484) by concatenating the rows of the adjacency matrix of the network into one binary string. As such, the network topology of 22 nodes is represented as a chromosome i.e. a binary string of length 484. The topology of the basic network N1 was changed randomly using mutation and crossover. The crossover points were randomly selected uniformly from the range of [1:484]. Generally, the mutation rate for any particular bit is less than 1% . In our implementation the mutation operator was applied to each of the bit in a chromosome (after performing crossover) with a low probability value of 0.01. Once the process of selection of chromosome, recombination and mutation is finished, the population of next generation is evaluated .
where cost = dist(s[i], t[j]), D is a matrix of size [0..n, 0..m], D[0, 0] = 0. Initially each entry of D[i, 0], for 0 <i ≤ n, and D[0, j], for 0 <j ≤ m, are set to infinity, i.e. a larger value which cannot be part of the data sequences. Here s[1..n] and t[1..m] are the two time series representing protein phosphorylation levels over time points to be compared, whereas s[i] and t[j] represents the data at time points i and j respectively. For any two numbers s[i] and t[j], dist(s[i], t[j]) represents the distance between the numbers, e.g. dist(s[i], t[j]) = |s[i] −t[j]|. The objective function aims to measure the goodness of fit between the simulation data and real data.
PLSR for simulation data from N1
Inferring the tumorigenic network N2
Due to inherent randomness in Genetic Algorithm, the edges added and deleted in N1 (while inferring N2) were different among different run of simulations. Some of the changes in the network were found to be more frequent compared to other. So, just few runs of simulation couldn't be relied upon to find the changes in the N1 network causing cancer. Therefore, to find consistent (or conserved re-wirings) changes to the network, we performed the simulation for 150 times for inferring N2 from N1 and another 150 rounds of simulation for inferring N3 from N2. The changes which occurred in the network with the highest frequency were selected to construct N2 (and subsequently N3). The most frequently removed edges in the N1 network while inferring N2 were SMAC-XIAP, Casp8-Casp3 and p53-PUMA. For 150 rounds of simulations, each of these deletions occurred with a frequency of 146, 143 and 141 respectively. The network edges found to be inserted in the N1 by the Genetic Algorithm with the highest frequencies were XIAP-Casp8 and TNFR-Stat3, with frequencies of 149 and 146.
We verified the various rewiring events using the existing literature and confirmed the validity for the above mentioned network changes. p53 is a tumour suppressor and controls the regulation of PUMA. PUMA induces apoptotic signals inside the cells. Less activity of PUMA leads to apoptosis deficiency which in turn leads to the increased risk of cancer . We also realised that SMAC down-regulates XIAP and XIAP down-regulates Casp3, a pro-apoptotic protein. So if SMAC is working properly, there will be more cell death leading to less tumorigenic behaviour by cells. But if SMAC is not able to down-regulates XIAP, there will be less apoptosis and so more chances of cancer . We also came across literature evidence highlighting the critical role of Casp8 for affecting breast cancer directly [5, 32]. STAT3 interacts with various molecules involved in programmed cell death, regulating their functions including MOMP formation, which leads to the release of the cytochrome c . XIAP inhibits the processing of Casp8. In fact, proteolytic processing of several caspases, including Casp9, is not allowed in the presences of XIAP. The lack of processing of Casp8 and Casp9 allows them to interact with Casp3 and promote apoptosis . TNFR activates the Stat3 signalling. The stimulation of TNFR leads the phosphorylation of the Stat3 and Stat5b and the phosphorylated molecules are trans-located into the nucleus .
Inferring the drug sensitive network N3
Sensitivity analysis of the model
To analyse the behaviour of our model with respect to the fluctuations in model parameters, we verified our model by performing sensitivity analysis for the rate constants. We initially tested apoptosis level for each of the molecules by reducing the parameter by 30%. Then we increased the parameter by 30%. Among all the parameters, "Casp3-Casp8" and "Casp3-Apop", were found to be very sensitive, affecting the apoptosis level to the maximum. We found that the level of apoptosis for most of the parameters changed only slightly, within +/-5%, except for the most sensitive parameters, "Casp3-Casp8" and "Casp3-Apop", which affected the level of apoptosis by +/-20%.
To test the robustness of our model, we also performed the perturbation test. We changed the initial concentration of each of the molecules and identified the most sensitive parameters of the model. The apoptosis level was predicted for each of the molecule whose initial concentration was reduced by 30%. Then, for each molecule we increased the initial concentration by 30%. We found that the level of apoptosis for most of the initial concentrations was stable, except for the concentration of the molecules with parameters of "Casp3-Casp8" and "Casp3-Apop". This suggests an overall robustness of our model.
In our proposed study, we used Genetic Algorithm to infer rewiring of the apoptotic network. The most frequent rewiring events are selected, and most of them were found to be consistent with existing literature. However, using Genetic Algorithm we may not find a globally optimal solution, as some of the network rewiring events might have been missed by the Genetic Algorithm based searching. So far we have included only 18 out of 32 proteins in the Yaffe's data. A network with more signalling data may help us understand the pathway changes in more comprehensive ways. In future, with expanded apoptosis network and more proteins, we would be able to detect more network alterations through comparisons between simulation data and experimental data. Also, beside Genetic Algorithm we plan to use other computational techniques (e.g. Simulated Annealing). In this paper Yaffes data set has been used. Our next goal is to construct a larger network model for cancer cell phenotypic responses which can simulate observations for some other datasets taken from multiple sources.
This work is supported by MOE AcRF Tier 2 grant (ARC39/13, MOE2013-T2-1-079), Ministry of Education, Singapore.
This article has been published as part of BMC Systems Biology Volume 9 Supplement 1, 2015: Selected articles from the Thirteenth Asia Pacific Bioinformatics Conference (APBC 2015): Systems Biology. The full contents of the supplement are available online at http://www.biomedcentral.com/bmcsystbiol/supplements/9/S1
- Hanahan Douglas, Robert Weinberg: The hallmarks of cancer. Cell. 2000, 100 (1): 5770-View ArticleGoogle Scholar
- Calzone Laurence, Tournier L, Fourquet S, Thieffry D, Zhivotovsky B: Mathematical modelling of cell-fate decision in response to death receptor engagement. PLoS Comput Biol. 2010, 66: e1000702-View ArticleGoogle Scholar
- Naldi A, Berenguier D, Faure A, Lopez F, Thieffry D, et al: Logical modelling of regulatory networks with ginsim 2.3. Biosystems. 2009, 97: 134-139. 10.1016/j.biosystems.2009.04.008.View ArticlePubMedGoogle Scholar
- Hong Ji-Young, Kim Geun-Hong, Kim Jun-Woo, Kwon Soon-Sung, Sato Eisuke, Cho Kwang-Hyun, Eun Bo Shim: Computational modeling of apoptotic signaling pathways induced by cisplatin. BMC Systems Biology. 2012, 6: 122-10.1186/1752-0509-6-122.PubMed CentralView ArticlePubMedGoogle Scholar
- Lee MJ, Ye AS, Gardino AK, Heijink AM, Sorger PK, Macbeath G, Yaffe MB: Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell. 2012, 149: 780-794. 10.1016/j.cell.2012.03.031.PubMed CentralView ArticlePubMedGoogle Scholar
- Carpenter RL, Lo HW: Regulation of apoptosis by her2 in breast cancer. J Carcinogene Mutagene. 2013, S7: 003-Google Scholar
- Zhang L, Yu J: Puma, a potent killer with or without p53. Oncogene. 2008, S71-S83.Google Scholar
- Weng C, Li Y, Xu D, Shi Y, Tang H: Specific cleavage of mcl-1 by caspase-3 in tumor necrosis factor-related apoptosis-inducing ligand (trail)-induced apoptosis in jurkat leukemia t cells. J Biol Chem. 2005, 280 (11): 1049-1500.View ArticleGoogle Scholar
- Buytaert E, Callewaert G, Vandenheede JR, Agostinis P: Deficiency in apoptotic effectors bax and bak reveals an autophagic cell death pathway initiated by photodamage to the endoplasmic reticulum. Autophagy. 2006, 2 (3): 238-40. 10.4161/auto.2730.View ArticlePubMedGoogle Scholar
- Kui Lei, Nimnual Anjaruwee, Zong Wei-Xing, Kennedy Norman, Flavell Richard, Thompson Craig, Bar-Sagi Dafna, Davis Roger: The bax subfamily of bcl2-related proteins is essential for apoptotic signal transduction by c-jun nh2-terminal kinase. Mol Cell Biol. 2002, 22 (13): 4929-4942. 10.1128/MCB.22.13.4929-4942.2002.View ArticleGoogle Scholar
- Zalckvar Einat, Berissi Hanna, Mizrachy Liat, Idelchuk Yulia, Koren Itay, Eisenstein Miriam, Sabanay Helena, Pinkas-Kramarski Ronit, Kimchi Adi: Dap-kinase-mediated phosphorylation on the bh3 domain of beclin 1 promotes dissociation of beclin 1 from bcl-xl and induction of autophagy. EMBO Rep. 2009, 10 (3): 285-292. 10.1038/embor.2008.246.PubMed CentralView ArticlePubMedGoogle Scholar
- Marquez Rebecca, Xu Liang: Bcl-2:beclin 1 complex: multiple, mechanisms regulating autophagy/apoptosis toggle switch. Am J Cancer Res. 2012, 2 (2): 214-221.PubMed CentralPubMedGoogle Scholar
- Bhattacharya S, Ray RM, Johnson LR: Stat3-mediated transcription of bcl-2, mcl-1 and c-iap2 prevents apoptosis in polyamine-depleted cells. Biochem J. 2005, 1;392 (Pt 2): 335-44.View ArticleGoogle Scholar
- Choi Hye-Jin, Han Joong-Soo: Overexpression of phospholipase d enhances bcl-2 expression by activating stat3 through independent activation of erk and p38mapk in hela cells. Biochim Biophys Acta. 2012, 1082-1091.Google Scholar
- Den Haese GJ, Walworth N, Carr AM, Gould KL: The wee1 protein kinase regulates t14 phosphorylation of fission yeast cdc2. Mol Biol Cell. 1995, 6 (4): 371-85. 10.1091/mbc.6.4.371.PubMed CentralView ArticlePubMedGoogle Scholar
- Pathan N, Aime-Sempe C, Kitada S, Basu A, Haldar S, Reed JC: Microtubule-targeting drugs induce bcl-2 phosphorylation and association with pin1. Neoplasia. 2001, 3 (6): 5509.-View ArticleGoogle Scholar
- Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A: The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer. 2001, 8: 11-31. 10.1677/erc.0.0080011.View ArticlePubMedGoogle Scholar
- Yu C, Minemoto Y, Zhang J, Liu J, Bui TN, Xiang J, Lin A: Jnk suppresses apoptosis via phosphorylation of the proapoptotic bcl-2 family protein bad. Mol Cell. 2004, 13 (3): 329-40. 10.1016/S1097-2765(04)00028-0.View ArticlePubMedGoogle Scholar
- Zhaoyu Jin, Wafik S, El-Deiry : Distinct signaling pathways in trail-versus tumor necrosis factor-induced apoptosis. Mol Cell Biol. 2006, 26 (21): 8136-8148. 10.1128/MCB.00257-06.View ArticleGoogle Scholar
- Funahashi A, Matsuoka Y, Jouraku A, Morohashi M, Kikuchi N, Kitano H: Celldesigner 3.5: A versatile modeling tool for biochemical networks. Proceedings of the IEEE. 2008, 96 (8): 1254-1265.View ArticleGoogle Scholar
- Mathworks: ode45:solve nonstiff differential equations. User's Guide (r2014b). Retrieved 2014, October 25, [http://www.mathworks.com]
- Zhang T, Brazhnik P, Tyson JJ: Computational analysis of dynamical responses to the intrinsic pathway of programmed cell death. Biophys J. 2009, 97: 415-434. 10.1016/j.bpj.2009.04.053.PubMed CentralView ArticlePubMedGoogle Scholar
- Herzel H, Legewie S, Blthgen N: Mathematical modeling identifies inhibitors of apoptosis as mediators of positive feedback and bistability. PLoS Comput Biol. 2006Google Scholar
- Aldridge BB, Zhang M, Lauffenburger DA, Sorger PK, Albeck JG, Burke JM: A novel epidermal growth factor receptor inhibitor promotes apoptosis in nonsmall cell lung cancer cells resistant to erloti. Mol Cell. 2008, 30 (1): 11-25. 10.1016/j.molcel.2008.02.012.PubMed CentralView ArticlePubMedGoogle Scholar
- Jones G: Genetic and evolutionary algorithms. Encyclopedia of Computational Chemistry. Edited by: Schleyer, P.v.R. et al. 1998, 1127: 1136-Google Scholar
- Kohonen Jukka: A brief comparison of simulated annealing and genetic algorithm approaches. 1999, Retrieved October 25, 2014, [http://www.cs.helsinki.fi/u/kohonen/papers/gasa.html]Google Scholar
- Whitley D: A genetic algorithm tutorial. Stat Comput. 1994, 65-85. 4Google Scholar
- Keogh E: Exact indexing of dynamic time warping. 2002, VLDB Hong Kong, China, 406-417.Google Scholar
- Ghazi Al-Naymat, Chawla Sanjay, Taheri Javid: Sparsedtw: A novel approach to speed up dynamic time warping. Proc. 8th Australian Data Mining Conference. 2009, 117-127. 101Google Scholar
- Janes KA, Yaffe MB: Data-driven modelling of signal-transduction networks. Nat Rev Mol Cell Biol. 2006, 820-828. 7Google Scholar
- Vogelstein B, Kinzler KW: Cancer genes and the pathways they control. Nat Med. 2004, 10 (8): 789-99. 10.1038/nm1087.View ArticlePubMedGoogle Scholar
- Camp NJ, Parry M, Knight S, Abo R, Elliott G, et al: Fine-mapping casp8 risk variants in breast cancer. Cancer Epidemiol Biomarkers Prev. 2011, 21 (1): 176-81.PubMed CentralView ArticlePubMedGoogle Scholar
- Larner AC, Szczepanek K, Lesnefsky EJ: Multi-tasking: Nuclear transcription factors with novel roles in the mitochondria. Trends cell Biol. 2012, 22: 429-437. 10.1016/j.tcb.2012.05.001.PubMed CentralView ArticlePubMedGoogle Scholar
- Stennicke HR, Van Arsdale T, Zhou Q, Srinivasula SM, Alnemri ES, Salvesen GS, Reed JC, Deveraux QL, Roy N: Iaps block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J. 1998, 17 (8): 2215-23. 10.1093/emboj/17.8.2215.PubMed CentralView ArticlePubMedGoogle Scholar
- Grilli A, Di Valerio V, Centurione L, Sabatino G, Garaci F, Zauli G, Bonvini E, Di Baldassarre A, Miscia S, Marchisio M: Tumor necrosis factor alpha (tnf-alpha) activates jak1/stat3-stat5b signaling through tnfr-1 in human b cells. Cell Growth Differ. 2002, 13 (1): 13-8.PubMedGoogle Scholar
- Olaussen KA, Zermati Y, Tasdemir E, Robert T, de La Motte Rouge T, Galluzzi L, et al: A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. Cancer Res. 2007, 67: 6253-6262. 10.1158/0008-5472.CAN-07-0538.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.